← Leaderboards
Charles Alexander Glass
Zacharon Pharmaceuticals, Inc.
$1,651,872
Attributed
$2,992,630
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–12$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,992,630 · 5
By mechanism
R44$1,999,108 · 1
R43$993,522 · 4
Top collaborators
- Brett E Crawford4 shared
Most similar at Zacharon Pharmaceuticals, Inc.
Same institution · by research overlap
- Brett E Crawford$3,953,297
- Jillian R Brown$1,377,386
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsHereditary DiseasePenetrationSmall MoleculeIn VivoAnalogInhibitor/AntagonistLysosomal Storage DiseasesPropertyEnzymesEnzyme DeficiencyCessation Of LifeBaseBoneBlood FlowBlood - Brain Barrier AnatomyBlocking AntibodiesAntibody FormationAnabolismCartilageCardiacAntibodiesDisease-Causing MutationBiology
Grant awards (6)
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999,781
R44 · FY2012 · NS
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999,327
R44 · FY2011 · NS
A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases$342,896
R43 · FY2011 · NS
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$339,513
R43 · FY2010 · NS
Inhibitors of Heparan Sulfate Biosynthesis and Cancer$196,245
R43 · FY2006 · CA · contact PI
Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs$114,868
R43 · FY2006 · NS · contact PI